ATLANTA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. ("RAPT Therapeutics,"?or the "Company") (NASDAQ:RAPT) complied with federal securities laws. On February 20, 2024, the Company "announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the [C]ompany's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive ...
RAPT) Announced by Holzer & Holzer, LLC>Full story available on Benzinga.com